Orion Pharma Selects ChemDiv as A Partner in Drug Discovery Services
SAN DIEGO, Nov. 30 /PRNewswire/ -- ChemDiv, Inc. and Orion Pharma todayannounced that Orion has chosen ChemDiv as a discovery partner in smallmolecule therapeutics for Orion's priority targets.
Under the terms of the agreement, ChemDiv will deploy the DiscoveryoutSource(TM) platform for Orion's discovery program, including the world'slargest commercially available chemical library, proprietary rational design,assay development, and bioscreening. ChemDiv will screen rationally designedchemical libraries against Orion's proprietary targets, and Orion will selecthit series for subsequent lead optimization. Financial terms and identity ofdrug targets were not disclosed. The agreement provides options for expandingthe discovery partnership.
"I am very satisfied with the commitment and exchange of information inour joint effort. We have a good basis for success," said Dr. Ari Koivisto,Orion's contact person in the collaboration. "Our partnership with ChemDivcomplements our in-house discovery effort in this particular project," statedDr. Antti Haapalinna, Director of Nonclinical R&D, Orion Pharma, OrionCorporation.
"We are delighted to offer discovery services to Orion Pharma in thispartnership. We are especially pleased with the constructive dialog with OrionR&D, based on our mutual understanding and shared goals. Based on ChemDiv'sdiligence and track record, we are confident of success and look forward toexpansion of this collaboration in the near future," commented NikolaySavchuk, President and CEO of ChemDiv, Inc.
About Orion Corporation
Orion Corporation (OMX: ORNAV, ORNBV) is one of the leading pharmaceuticalcompanies in the northern Europe. Orion develops, manufactures and marketspharmaceuticals, active pharmaceutical ingredients and diagnostic tests forglobal markets. Pharmaceuticals generate about 95% of the Group's net sales,of which proprietary patented pharmaceutical innovations contribute aconsiderable part. The core therapy areas in Orion's product and researchstrategy are central nervous system disorders, cardiology and critical care,urology and oncology. Stalevo(R) and Comtess(R) / Comtan(R), treatmentsoriginated by Orion for Parkinson 's disease, are the largest products bysales in Orion's portfolio. For additional information, please visithttp://www.orion.fi.
About ChemDiv, Inc.
ChemDiv (http://www.chemdiv.com) is a global chemistry-driven contractresearch organization focused on identifying and delivering pre-clinicalopportunities and advanced R&D services for the development of treatments forlife-threatening diseases. For over 17 years, ChemDiv has provided itsDiscovery outSource(TM) solutions to life science partners, includingmedicinal and synthetic chemistry, pre-clinical development, screeninglibraries, and global logistics. ChemDiv's international research teamencompasses 550 chemists and biologists in San Diego and Moscow based R&Dcenters.SOURCE ChemDiv, Inc.Ron Demuth, General Manager of ChemDiv, Inc., +1-858-794-4860, Fax,+1-858-794-4931, rdemuth@chemdiv.com
Follow Reuters